Wednesday, October 15th 2014
Dr. Petra Schneider,Blackfield AG, Germany
Computational analysis of human- and mouse-specific next-generation sequencing data in mixed tissue samples
Blackfield is a young biotechnology company supporting pharmaceuticalcompanies in developing targeted cancer drugs. We offer to derivegenetic tumor profiles from next-generation sequencing (NGS) data.Computational analysis of the raw sequencing data using proprietaryalgorithms is a key step in this process, due to the massive amount ofdata generated by NGS platforms. In this talk, I will outline thegeneration and analysis of NGS data, and I will present the novelstrategy we integrated recently in our computational analysis pipelineto deal with contaminated tumor samples. Artificial validation samplesdemonstrate in a controlled setting how this approach influencesmutation calling or gene expression analyses.
Colloquium coordinators are Prof.dr. M. Aiello (e-mail :
Prof.dr. M. Biehl (e-mail:
Effective immediately, UG-authors are entitled to a discount when publishing open access in one of the 271 journals from publisher MDPI. Corresponding authors from the UG will receive a 10% discount on the article processing charge. The only...
This year, the University of Groningen has submitted four research projects to compete for the national Klokhuis Science Prize. The aim of this prize is to introduce a young and wide audience to academic research. The winning project will be...
Non-executive directors (hereafter: directors) have to take a critical stance towards the top managers they supervise. This has been the dominant perspective among researchers and the media after the financial crisis of 2008 and recent major...